Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Gains from Investment Securities (2016 - 2025)

Spero Therapeutics' Gains from Investment Securities history spans 10 years, with the latest figure at $414417.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 85.28% year-over-year to $414417.0; the TTM value through Dec 2025 reached $414417.0, down 85.28%, while the annual FY2025 figure was $414417.0, 85.28% down from the prior year.
  • Gains from Investment Securities reached $414417.0 in Q4 2025 per SPRO's latest filing, roughly flat from $414417.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.9 million in Q4 2021 to a low of $26521.0 in Q1 2023.
  • Average Gains from Investment Securities over 5 years is $1.6 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: tumbled 97.22% in 2023, then surged 10763.33% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $4.9 million in 2021, then tumbled by 97.14% to $140000.0 in 2022, then skyrocketed by 1479.29% to $2.2 million in 2023, then rose by 27.31% to $2.8 million in 2024, then plummeted by 85.28% to $414417.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Gains from Investment Securities are $414417.0 (Q4 2025), $414417.0 (Q3 2025), and $2.6 million (Q2 2025).